‘Tariffs on Indian pharma would burden American consumers’

India’s Pharmaceutical Export Promotion Council (Pharmexcil) said on Thursday that exempting drug formulations and active pharmaceutical ingredients (API) from tariffs reiterates that India manufactures low-cost essential generic drugs and any rise in their costs will ultimately burden the American consumers.